Magenta Therapeutics Inc (NQ: MGTA )

8.210 USD -0.080 (-0.97%)

Official Closing Price Updated: 4:03 PM EST, Jan 22, 2021 Add to My Watchlist

Price and Volume

Volume	151,500
Open	8.180
Bid (Size)	8.000 (1)
Ask (Size)	8.700 (3)
Prev. Close	8.290
Today's Range	8.100 - 8.401
52wk Range	5.760 - 14.25
Shares Outstanding	34,370,267
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Anne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech’s Board of Directors and Chair of the Audit Committee

January 12, 2021

CitiusTech, a leading provider of healthcare technology services and solutions, announced today that Anne McGeorge, former Managing Partner of Grant Thornton’s Global Health Care and Life Sciences...

Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials

January 11, 2021

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more...

Performance

YTD	+7.18%	+7.18%
1 Month	+6.62%	+6.62%
3 Month	+21.63%	+21.63%
6 Month	+9.91%	+9.91%
1 Year	-40.68%	-40.68%

More News

Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 05, 2021

Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditionin

December 07, 2020

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell

December 04, 2020

Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer

November 09, 2020

Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results

November 05, 2020

Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting

November 04, 2020

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September

September 11, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

July 15, 2020

Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV

September 02, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.